# The Development of Radiolabeled PSMA Agent with Low Salivary Gland Uptake

> **NIH NIH R41** · TRIPILL BIOTECHNOLOGY, CORP. · 2024 · $399,981

## Abstract

Project Abstract
Widely overexpressed in prostate cancer tissues, Prostate Specific Membrane Antigen (PSMA) has become an
attractive target for both imaging and radionuclide-based therapy of prostate cancer. Despite exciting progress,
PSMA-targeted therapeutic agents could pose high radiation exposure toward normal organs that express the
receptor. In fact, salivary glands (SGs) are often the dose-limiting organ that determines how much
radioactivity can be administered, patient eligibility, and the treatment outcome thereafter. This application
addresses critical needs to reduce radiation exposure to normal organs while maintaining tumor uptake. We
therefore focus on constructing PSMA derivatives aiming to protect SGs from these radiolabeled agents.
In recent years, tremendous excitement has emerged over probes that can be diagnostic and therapeutic
(Theranostics). These agents not only can reveal disease sites but also emit radiation that can have therapeutic
effects, enabling localized and targeted treatments. Recently, the UNC team has established a trifunctionalized
TVS system to streamline the workflows to develop theranostic agents (patent pending and Tripill Biotech is
negotiating with UNC to license the technology). In our preliminary research, we have discovered that NOTA-
UNC-PSMA2 can demonstrate 2-3 times higher tumor uptake in rodent models (compared with PSMA-617),
while the SG uptake is only 1/10th of PSMA-617 at 24 h post-injection in non-human primates (NHP), potentially
due to the cation binding ability of the TVS system. These encouraging results clearly demonstrated the feasibility
of selectively reducing SG uptake with minimal impact on tumor uptake of PSMA-positive tumors. With the
promising imaging component completed in preliminary research, in this project, Tripill Biotech will partner with
Prof. Wu to validate the therapeutic potential of NOTA-UNC-PSMA2. The resulting agents will be labeled with
64Cu and 67Cu, and evaluated for stability, PSMA binding affinity, salivary gland uptake, and in vivo therapeutic
efficacy. This application reflects a joint effort from a multidisciplinary team composed of experts in chemistry,
drug delivery, radiochemistry, biology, clinical practice, and molecular imaging. The success of the proposed
approach would solve key issues in PSMA-targeted radiotherapeutics (in this case exposure to SGs), which
could greatly benefit prostate cancer management.

## Key facts

- **NIH application ID:** 10920706
- **Project number:** 1R41CA285188-01A1
- **Recipient organization:** TRIPILL BIOTECHNOLOGY, CORP.
- **Principal Investigator:** Zhanhong Wu
- **Activity code:** R41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $399,981
- **Award type:** 1
- **Project period:** 2024-08-01 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10920706

## Citation

> US National Institutes of Health, RePORTER application 10920706, The Development of Radiolabeled PSMA Agent with Low Salivary Gland Uptake (1R41CA285188-01A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10920706. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*